Cimzia
(Certolizumab Pegol)ApprovedMonoclonal antibody
UCBThis drug is used to treat inflammatory conditions like rheumatoid arthritis, Crohn's disease, and psoriasis by reducing the immune system's inflammatory response. It helps decrease pain, swelling, and other symptoms caused by these conditions.[2] Cimzia is currently approved and in use across 5 indications[4].[1]
Cimzia is one of 99 biologic programs targeting Immune System Disease. It is currently in Approved.
5
Indications
81
Total Trials
2
Active Trials
98
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
55 competitors in Immune System Disease
#DrugCompanyPhaseTrials
1Cimzia
UCBApproved
Thalomid
Bristol-Myers SquibbApproved
Cellcept
RocheApproved
Trexall
Jazz PharmaceuticalsApproved
Avelox
BayerApproved
Neoral
NovartisApproved
Tecfidera
BiogenApproved
Medrol
PfizerApproved
Crestor
AstraZenecaApproved
Otezla
AmgenApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis30 trials
Show 27 more trials
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)
Completed·—·Phase 3·NCT01374971·12 enrolled
Crohn's Disease15 trials
Show 12 more trials
Psoriasis7 trials
Show 4 more trials
Crohn's Disease (CD)3 trials
19 more indications
Remission2 trials
Interstitial Cystitis1 trial
Concentration1 trial
Moderate to Severe Crohn's Disease1 trial
Ankylosing Spondylitis1 trial
Psoriatic Arthritis1 trial
Efficacy and Safety1 trial
ESS1 trial
Adult1 trial
Induction Therapy1 trial
Takayasu arteritis1 trial
AxSpA1 trial
Treatment1 trial
Chronic Plaque Psoriasis1 trial
Axial Spondyloarthritis1 trial
Unspecified4 trials
Show 1 more trial
Regulatory
FDA Approval Timeline[5]
Apr 22, 2008
CIMZIA
BLA BLA125160
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Cimzia drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Certolizumab Pegol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]